Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in previously untreated Subjects with Acute Myeloid Leukemia who ar… Ended

2024-513631-25-00 Acute Myeloid Leukemia 5 2017-08-17
This is clinical study to test, for the first time in people, the safety (any good or bad effects), how long the drug can stay in the body a… Ended

2023-509969-20-00 Part C: advanced or unresectable STs (Spain only) 1 2017-07-24
A prospective, multicenter, phase-II trial of ibrutinib plus venetoclax in physically fit patients with creatinine clearance ≥ 30 ml/min who… Ended

2023-510557-42-00 chronic lymphocytic leukemia 4 2017-07-10
A phase I dose finding study of oral TNO155 in adult patients with advanced solid tumors Ended

2023-508925-29-00 Advanced solid tumors 1 2017-06-29
ABIMMUNE: A Phase I/II study evaluating the safety and clinical activity of anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) a… Ended

2024-514920-18-00 Metastatic squamous cell carcinoma of head and neck, lu 9 2017-06-20
Study of Nivolumab plus Ipilimumab, Ipilimumab or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer Ended

2022-502909-15-00 Metastatic Castration-Resistant Prostate Cancer 4 2017-06-09
Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic cas… Ended

2024-511660-89-00 metastatic castration resistant prostate cancer (mCRPC) 4 2017-06-09
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3… Ended

2022-501251-81-00 Renal cell carcinoma 5 2017-06-08
CheckMate 901: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 901 Ended

2022-501784-40-00 Untreated Unresectable or Metastatic Urothelial Cancer 5 2017-05-26
Multicenter open-label, phase II trial, to evaluate the efficacy and safety of nal-IRI for progressing brain metastases in patients with HER… Ended

2024-514999-41-00 HER2 negative metastatic breast cancer (MBC) with nervo 4 2017-04-28
A Neoadjuvant Study of Nivolumab plus Ipilimumab or Nivolumab plus Chemotherapy versus Chemotherapy alone in Early Stage Non-Small Cell Lung… Ended

2022-501360-18-00 Early Stage Non-Small Cell Lung Cancer (NSCLC) 5 2017-03-15
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab plus Chemotherapy vs Placebo plus Chemotherapy as Neoadjuvant Therapy … Ended

2022-501382-49-00 Triple Negative Breast Cancer (TNBC) 5 2017-03-07
A phase I/II multicenter trial evaluating the association of hypofractionated stereotactic radiation therapy and the anti-PD-L1 Durvalumab (… Ended

2024-515000-39-00 Recurrent glioblastoma. 9 2017-01-17
Phase III randomised trial evaluating FOLFOX with or without DOCETAXEL (TFOX) as 1st line chemotherapy for locally advanced or metastatic oe… Ended

2024-515221-29-00 Locally advanced or metastatic oesogastric adenocarcino 10 2016-12-19
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexametha… Ended

2024-511967-26-00 AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis 5 2016-11-21
A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone… Ended

2024-512474-98-00 Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutati 5 2016-11-07
GIVE trial (Gazyvaro In combination with VEnetoclax in Elderly CLL) Ended

2024-511048-22-00 Chronic lymphocytic leukemia 4 2016-10-27
A trial of BMS-986012 in combination with chemotherapy for small cell lung cancer Ended

2024-511824-15-00 Extensive-Stage Small Cell Lung Cancer 9 2016-10-18
Pembrolizumab in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma Ended

2023-507294-18-00 Metastatic renal cell carcinoma 5 2016-09-16
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovar… Ended

2023-508010-42-00 Homologous recombination deficiency advanced ovarian ca 5 2016-09-14
ROLLOVER STUDY FOR TAZEMETOSTAT Ended

2023-510553-41-00 Subjects will receive tazemetostat as dictated in their 9 2016-08-29
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea… Ended

2024-511235-10-00 Generalized mantle cell Lymphoma 5 2016-07-25
Tepotinib Phase II study in advanced lung cancer harboring MET exon 14 (METex14) skipping alterations and MET amplification Ended

2024-512003-39-00 Lung Cancer 4 2016-07-18
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 5 2016-07-15